March 31, 2011 03:04 PM Eastern Daylight Time 

COLORADO SPRINGS, Colo.–(BUSINESS WIRE)–Cannabis Science, Inc. (OTCBB:CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to report a government released update on cancer treatments using medical cannabis (marijuana) cancer.gov/cancertopics/pdq/cam/cannabis/healthprofessional and cancer.gov, updated March 17, 2011, summarizing how the treatment of cancer with cannabinoids goes beyond the simple treatment of symptoms and side effects by exhibiting possible direct antitumor activities.

“in the practice of integrative oncology, the health care provider may recommend medicinal Cannabis not only for symptom management but also for its possible direct antitumor effect.”

This summary contains the following key information:

Robert Melamede, Ph.D., Cannabis Science’s CEO stated, “As we’ve previously reported, one of the most interesting findings that has emerged since the discovery of the endocannabinoid system (marijuana like compounds produced by humans, and all vertebrates) is that cannabinoids have profound cancer-killing and anti-metastatic properties. There is strong scientific support, demonstrated in tissue culture and animal studies, of the potent cancer killing properties of cannabinoids for such deadly cancers as glioma, lung cancer, breast and prostate cancer, leukemias and lymphomas, and as well as skin cancers.

currently the federal government prohibitionist position on cannabis is hindering the medical community by delaying vitally important clinical cannabis research. I was quite elated when I recently saw that the NCI posted on their webpage “In the practice of integrative oncology, the health care provider may recommend medicinal Cannabis not only for symptom management but also for its possible direct antitumor effect.” I foolishly thought that finally there would be official recognition of the modern peer reviewed science that shows the cancer killing properties of cannabinoids. Sadly, this statement was removed, without comment, within hours of its posting.”

Dr. Melamede goes on to say “Clinical trials are desperately needed. Cannabis Science is actively working on arrangements that will allow us to perform the necessary clinical trials to verify, or not, the numerous anecdotal reports demonstrating what appears to be cancer cures. These observations are occurring with greater frequency since numerous states have legalized the medical use of cannabis. Cannabis in various forms has been used by different cultures for thousands of years as a viable medicine for numerous ailments. in fact, some biblical translations even indicate that cannabis (keneh bosem) was a component of the “Holy Anointing Oil.” Current cannabis science simply provides evidence that supports the widespread historical use of oral, cannabis-based medicines that was driven by it’s success in treating illnesses.”

about Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. the Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. in sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

forward looking Statements

forward looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

1. Adams IB, Martin BR: Cannabis: pharmacology and toxicology in animals and humans. Addiction 91 (11): 1585-614, 1996. [PUBMED Abstract]